CuraSen’s SPARK

After debuting with a $54.5 million series A round, CuraSen Therapeutics Inc. hopes to generate clinical proof-of-concept data for at least two neurodegenerative disease programs in the next three years.

New Leaf Venture Partners led the round, which closed on Oct. 17. Funds managed by Tekla Capital, Alta Partners, Johnson & Johnson Innovation - JJDC Inc. and Pappas Capital also participated...